14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today AUPH ranks #12642 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Aurinia Pharmaceuticals Inc Stock Forecast NASDAQ:AUPH

$18.67 (-7.30%)

Volume: 7M

Closed: Dec 03, 2021

Hollow Logo Score: -3.053

Aurinia Pharmaceuticals Inc Stock Forecast

$18.67 (-7.30%)

Volume: 7M

Closed: Dec 03, 2021

Score Hollow Logo -3.053
Which way will AUPH go? Request
Key Stats
Beta 0.83
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 26 and the stock is currently not being overbought or oversold

Volatile ride for Aurinia Pharmaceuticals Inc stock price on Friday moving between $18.40 and $21.24
(Updated on Dec 03, 2021)


Sell candidate since 2021-12-03

The Aurinia Pharmaceuticals Inc stock price fell by -7.30% on the last day (Friday, 3rd Dec 2021) from $20.14 to $18.67. During the day the stock fluctuated 15.43% from a day low at $18.40 to a day high of $21.24. The price has fallen in 7 of the last 10 days and is down by -37.05% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -6 million shares and in total, 7 million shares were bought and sold for approximately $122.57 million.

The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $17.95 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 17.4% during the next 3 months and, with a 90% probability hold a price between $21.07 and $41.20 at the end of this 3-month period.

Signals & Forecast

A buy signal was issued from a pivot bottom point on Wednesday, December 01, 2021, and so far it has risen 5.01%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Aurinia Pharmaceuticals Inc stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $18.97 and $25.90. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss

Aurinia Pharmaceuticals Inc finds support from accumulated volume at $18.34 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $2.84 between high and low, or 15.43%. For the last week, the stock has had a daily average volatility of 11.76%.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Aurinia Pharmaceuticals Inc stock A Buy?

The Aurinia Pharmaceuticals Inc stock holds several negative signals and despite the positive trend, we believe Aurinia Pharmaceuticals Inc will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Hold/Accumulate to a Sell candidate.

Current score: -3.053

Predicted Opening Price for Aurinia Pharmaceuticals Inc of Monday, December 6, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 6, 2021 Current price
$19.44 $18.67 (Undervalued)
Sell Candidate Downgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

On Nov 04, 2021 "Oppenheimer" gave "$32.00 - $33.00" rating for AUPH. The price target was set to $31.04+2.1%.

Volatility and Risk
Daily Average Volatility: 11.76 %
Overall Risk: Very High High Medium Low Very Low
Volatility
11.76 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $19.36
Price: $18.67
Support: $18.34

AUPH Insider Trading Show all Trades

INSIDER POWER

0.695

Last 100 transactions
Buy: 1 575 881 | Sell: 2 267 636 (Shares)
Date Action Amount Person Type
Nov 11, 2021 Sell 100 000 Solomons Neil Stock Option (right to buy)
Nov 11, 2021 Sell 30 000 Solomons Neil Stock Option (right to buy)
Nov 11, 2021 Sell 100 000 Solomons Neil Common Stock
Nov 11, 2021 Buy 100 000 Solomons Neil Common Stock
Nov 11, 2021 Sell 29 000 Martin Michael Robert Stock Option (right to buy)
Show all Insider Trades
INSIDER POWER

0.695

Last 100 transactions
Buy: 1 575 881 | Sell: 2 267 636 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 22.28 19.32 %
21.19 13.51 %
20.52 9.92 %
Current price: 18.67
Support 18.35 -1.70 %
17.68 -5.29 %
16.60 -11.11 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 20.14 7.87 %
19.65 5.25 %
19.36 3.70 %
Current price 18.67
Support 18.34 -1.77%
18.15 -2.79%
17.78 -4.77%

Click to get the best stock tips daily for free!

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Aurinia Pharmaceuticals Inc., a clinical stage pharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company’s lead drug candidate is Voclosporin, a calcineurin inhibitor, which is in Phase IIb clinical trial for the treatment of lupus nephritis. It has a collaboration agreement with Paladin Labs Inc. to maintain the patent portfolio for Voclosporin in Canada, South Africa, and Israe... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT